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Unexpected DNA binding properties with
correlated downstream biological applications in
mono vs. bis-1,8-naphthalimide Ru(II)-polypyridyl
conjugates†
Gary J. Ryan,a Fergus E. Poynton,a Robert B. P. Elmes,‡a Marialuisa Erby,b
D. Clive Williams,*b Susan J. Quinn*c and Thorfinnur Gunnlaugsson*a
The synthesis, spectroscopic characterisation and biological evaluation of mono- and bis-1,8-naphthal-
imide-conjugated ruthenium(II)-polypyridyl complexes is presented. Spectroscopic DNA titrations,
together with denaturation studies, show strong binding of both species to DNA through the naphthal-
imide arms. Linear and circular dichroism (LD and CD) spectroscopy reveal close association of the
Ru(bpy)3
2+ core with DNA in the case of the mono-naphthalamide complex, [Ru(bpy)2(bpy-NAP)]
2+. Sig-
nificantly, binding by the second naphthalimide arm in the [Ru(bpy)2(bpy-NAP2)]
2+ complex is found to
displace the Ru(bpy)3
2+ centre from the DNA backbone. This ‘negative allosteric effect’ is found to have a
dramatic influence on the photoinduced damage of plasmid DNA, and the viability of HeLa cancer cells
upon photoactivation. Overall the study clearly maps and correlates the relationship between molecular
structure, in vitro binding and activity, and in cellulo function.
Introduction
The development of transition metal polypyridyl complexes
capable of targeting DNA has been extensively investigated in
recent times.1–5 This has been largely motivated by the desire
to probe DNA-based chemical processes with the view of devel-
oping novel therapeutic agents.6–8 Ru(II)-polypyridyl complexes
show particular promise due to their water solubility, chemical
and kinetic inertness and spectroscopic properties such visible
light absorbance and photoluminescence.4,9 They have been
shown to be internalised by cells, with a variety of mechanisms
proposed including endocytosis, active transport and passive
diffusion, or through the use of vectors or delivery molecules
such as polypeptides.10–13 Tuning the polypyridyl ligand struc-
ture confers diverse functionality leading to intercalating com-
plexes capable of ‘light-switching’ signalling phenomena, and
strong DNA binding and photoinduced reactivity with
DNA.14–19 Furthermore, we have recently shown that such com-
plexes, based on simple bpy and phen ligands, when conju-
gated via an alkyl thio-linker to the surface of gold
nanoparticles can be employed for luminescent imaging
within cancer cells.20 We are interested in combining these
features to develop molecules as dual imaging and therapeutic
agents. Molecules can bind to DNA through a number of
modes.6,7,21 Ru(II)-polypyridyl systems have been shown to
bind to DNA by various modes, e.g. through intercalation,
groove binding and electrostatic interactions.22–29 We have
also developed several examples of DNA targeting binders,
based on the use of 1,8-naphthalimide derivatives.30–38 Such
structures have tuneable electronic properties, and have been
shown to exhibit good DNA binding affinity through either
intercalation or groove binding.39–44 In addition to being
effective DNA intercalators or groove binders, the 1,8-naphthal-
imides can also act as sensitising antenna for the Ru(II)-based
metal-to-ligand charge transfer (MLCT) emission, allowing for
the population of the excited state using two excitation chan-
nels.45 Herein, we present two new DNA targeting Ru(II) com-
plexes, [Ru(bpy)2(bpy-NAP)]
2+ (Ru·Nap) and [Ru(bpy)2(bpy-
NAP2)]
2+ (Ru·2Nap), Fig. 1, based on the conjugation of one or
two 1,8-naphthalimide units, respectively, to the polypyridyl
complexes via a flexible alkyl spacer. The rational design of
these complexes is based on combining (a) the DNA affinity
and (b) the lipophilic nature of the naphthalimide group to
facilitate more efficient binding of such Ru(II) complexes to
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DNA in a cooperative manner,38 and potentially enhance cellu-
lar uptake.36 To fully explore the activity of the complexes a
detailed in vitro photophysical study was completed in the
absence and presence of DNA.
Two distinct ligand-dependant DNA binding modes were
observed. In the mono-naphthalimide complex intercalation of
the naphthalimide brings the Ru(II)-polypyridyl centre in close
proximity to the DNA sugar phosphate backbone, which facili-
ties efficient DNA cleavage upon photoirradiation. However,
then in the case of Ru·2Nap the binding interaction of the
second naphthalimide arm to DNA, reduces interaction of the
Ru(II)-polypyridyl centre with the DNA backbone. Conse-
quently, this complex is found to be a less effective photo-
cleavage agent. This ‘negative allosteric effect’ leads to
different biological activity of the Ru·Nap and Ru·2Nap com-
plexes within HeLa cervical cancer cells and demonstrates how
a simple design modification to the polypyridyl ligand can
lead to modulated photophysical properties and downstream
biological activity of such Ru(II)–polypyridyl–naphthalimide
conjugates. This phenomenon, has to the best of our knowl-
edge, not been demonstrated before for such systems and can
have significant consequences on the ‘function’ or application
(i.e. therapeutic vs. diagnostic) of such complexes in chemical
biology.
Results and discussion
Synthesis of Ru·Nap and Ru·2Nap
The mono-substituted naphthalimide complex Ru·Nap and
the bis-substituted complex Ru·2Nap were synthesised in high
yield, as demonstrated in Scheme 1. Firstly, the 1,8-naphthal-
imide 1, was formed using the mono-protected Boc diamine,
N-(tert-butoxycarbonyl)-1,5-diaminopentane, giving 2 after
BOC-deprotection using TFA. The naphthalimide 2 was then
reacted with the appropriate 2,2′-bipyridine acid chloride
under anhydrous conditions to give 3a and 3b in 83 and 95%
yield, respectively, after initial aqueous acid workup, followed
by further purification using silica column chromatography.
This was followed by complexation of 3a and 3b with Ru-
(bpy)2Cl2. For both, the reaction mixture was heated at reflux
under an argon atmosphere for 20 h, followed by purification
involving, treatment with concentrated aqueous solution of
NH4PF6, which resulted in the formation of the PF6
− salts.
These were purified using silica flash column chromatography
by eluting the sample using the solvent mixture CH3CN : H2O :
NaNO3(sat) (40 : 4 : 1). The Cl
− salts of these complexes were
then regenerated by stirring a solution of either Ru·Nap and
Ru·2Nap in MeOH with Amberlite ion exchange resin. The Cl−
salts were then further purified by column chromatography on
Fig. 1 The Ru(II) based naphthalimide complexes Ru·Nap and Ru·2Nap.
Scheme 1 Synthesis of Ru·Nap and Ru·2Nap. Reagents and conditions: (i) anhyd. toluene, Et3N,reflux 24 h (ii) TFA/CH2Cl2 1 : 1, RT 1 h, (iii) dry
CH2Cl2, Et3N, RT 12 h, (iv) Ru(bpy)2Cl2, DMF/H2O, Ar, reflux, 24 h to yield Ru·NAP (86%) and Ru·2Naph (76%). Inset: controls, Ru and Nap, synthesised
for this study.
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Sephadex LH-20, eluting with MeOH, giving the products as
red/brown solids in 86 and 76% yields, respectively. Both
Ru·Nap and Ru·2Nap were fully characterised (See Experi-
mental). The distinct units of the complexes were readily dis-
cerned by NMR (CD3CN and CD3OD, 400 MHz) (See ESI
Fig. S1–S7†). CHN analysis showed the formation of the
desired products in high purity.
UV-vis absorption spectra
Having successfully synthesised both Ru·Nap and Ru·2Nap
their various photophysical properties were evaluated. The UV-
vis absorption spectra were recorded in buffered pH 7.0
aqueous solution, and show distinctive spectroscopic signals
for both the Ru(II) MLCT-based absorption and that of the
naphthalimide, see Fig. 2a and b. In the case of Ru·Nap an
intense band was observed at 286 nm, which was mainly
attributed to π–π* intraligand (IL) transitions. The band at
338 nm was assigned to the π–π* 1,8-naphthalimide tran-
sitions and the visible absorption band at 459 nm to the
MLCT transitions of the Ru(II) centre. The presence of the
amide substituted bipyridine ligands causes the MLCT band
to be somewhat broadened and red shifted compared to that
of Ru(bpy)3
2+.46 In the case of the bis-naphthalimide system
Ru·2Nap the presence of the additional amide group results in
a shift in the bands at 338 and 459 nm to 345 and 480 nm
respectively, see Fig. 2b. 1,8-Naphthalimides are known to
interact through π-stacking and in Ru·2Nap this can occur
intramolecularly between the two naphthalimides, or between
a naphthalimide and a bipyridine ligand.47,48 For this reason,
the existence of electronic interactions in the ground state
were considered by constructing an additive spectrum using a
suitable Ru(II) complex, Ru and a water soluble 1,8-naphthal-
imide derivative, Nap, see Fig. 3. Comparison of the summed
spectra with that of Ru·2Nap reveals a number of differences.
Firstly, the MLCT region is found to be less absorbing (by
22%) in Ru·2Nap. This strongly suggests electronic interaction
between the Ru(II) centre and the 1,8-naphthalimide in the
ground state. It is also worth noting that the IL transitions at
286 nm are also affected. Secondly, the band hypochromism
was found to be more pronounced in the region of the 1,8-
naphthalimide absorptions, at 230 and 345 nm, respectively.
In particular, the absorbance at 345 nm is reduced by ca. 47%,
in comparison to that observed for the additive spectrum.
These observations suggest that significant intramolecular
stacking interactions of the 1,8-naphthalimides occur in
solution.49
Emission spectra
Excitation of Ru·Nap and Ru·2Nap at 450 nm results in single
band emission at 645 and 670 nm respectively, see Fig. 2. The
amide substituted bipyridine ligands results in a red-shifted
emission compared to that observed for Ru(bpy)3
2+, which
typically emits at ca. 605 nm.50 For both complexes significant
contribution to MLCT-based emission is observed upon
naphthalimide excitation, which suggests the presence of
efficient singlet–singlet energy transfer, from the 1naphthal-
imide to the 1MLCT excited state. Evidence for this is clearly
seen in the excitation spectra of these derivatives, see Fig. 2a
and b, and by comparing these excitation spectra to that of the
control Ru complex (See ESI Fig. S8†). Indeed, the absorption
and excitation spectra are close to being super-imposable. The
contribution to the Ru(II) emission from the 1,8-naphthal-
imides was found to be much greater for Ru·2Nap than
Ru·Nap, which indicates that the second 1,8-naphthalimide
Fig. 2 UV/visible, excitation and emission spectra of (a) Ru·Nap (6.5 μM)
and (b) Ru·2Nap (6.5 μM) in 10 mM phosphate buffer, at pH 7.
Fig. 3 UV/visible absorption spectra of Ru·2Nap (6.5 μM) ( ), Ru
(6.5 μM) ( ). Nap (13 μM) ( ) and Ru + Nap (------). All samples
recorded in 10 mM phosphate buffer at pH 7.
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enhances this effect. The observation of very weak naphthal-
imide emission for both complexes is a further indication of
energy transfer to the Ru(II)-polypyridyl centre. This process is
represented schematically in Fig. S9 ESI.†
The quantum yields for both systems, recorded in buffered
aqueous solution, compared well with that obtained for the
control Ru ΦRu-MLCT = 0.014 (all excitation at 450 nm), see
Table 1. These results confirm the absence of any quenching
of the MLCT based emission by the naphthalimide, which is
expected as the naphthalimide centre is not sufficiently oxi-
dising to accept an electron from the excited states of the
Ru(II) complex (as deduced from a simplified Rehm–Weller
equation, where the driving force for electron transfer was
calculated to be approximately 0.12 eV for Ru·Nap and 0.26 eV
for Ru·2Nap, see ESI eqn (S1)†).51 The positive free energy
changes calculated for both systems render electron transfer
from the excited Ru(II) complex to the 1,8-naphthalimide
thermodynamically unfavourable in both cases. Quantum
yield determination for Ru·2Nap in dry acetonitrile under
aerated and degassed conditions revealed the complex emis-
sion to be quenched by dissolved oxygen (Table 1). Further-
more, the close agreement in the quantum yield values
determined for Ru·2Nap and Ru suggests the absence of an
equilibrium between the triplet excited state of the 1,8-
naphthalimide and that of the Ru(II) complex. The presence of
such equilibrium would be expected to greatly enhance the
lifetime of Ru·2Nap over that of the reference complex. Having
established the steady-state spectroscopic properties, the com-
plexes were next studied in the presence of DNA to establish
the influence of binding interactions.
DNA binding: absorption titrations
The DNA binding properties of the complexes was probed by
monitoring absorption bands of the naphthalimide and the
Ru(II) centre. In the case of the mono-naphthalimide Ru·Nap,
the addition of increasing concentrations of salmon testes’
DNA (st-DNA) resulted in a 37% hypochromism of the 1,8-
naphthalimide band at 338 nm (Fig. 4a). Such a large change
in the absorbance is characteristic of intercalation.35,36,40,41
A significant change was also observed in the absorbance of
the MLCT band, which decreased by 16%. In comparison the
control Ru complex undergoes a 9% hypochromic shift at the
MLCT band, which is attributed to electrostatic interactions
with the phosphate backbone of DNA.27 The intrinsic binding
constant of 9.0 × 106 M−1 was derived from a binding isotherm
using the model of Bard et al.52 and a binding site size of 2.18
base pairs was calculated, see Table 2. This is an order of mag-
nitude higher than the binding observed for either the
naphthalimide Nap or ruthenium metal centre, Ru(bpy)3
2+, Ru
separately and confirms the presence of cooperative binding.
When the titration was repeated for Ru·2Nap even greater
changes in the absorption spectrum were observed, see
Fig. 4b. A large, 56%, hypochromic shift was observed in the
naphthalimide band at 345 nm. However, more strikingly, a
41% decrease was observed for the MLCT band. The magni-
tude of the hypochromic shift is more than twice that observed
for the mono-naphthalimide complex. These observations
show that the environment of both the naphthalimide and the
metal centre of Ru·2Nap is significantly altered in the presence
of DNA, which also is the case for Ru·Nap. While, partial inter-
calation of the Ru(II) complex may also be possible, it is
Fig. 4 Changes in the UV/vis spectrum of (a) Ru·Nap (6.5 μM) upon
addition of st-DNA (0–21.45 μM base pairs) and (b) Ru·2Nap (6.7 μM)
upon addition of st-DNA (0–29.25 μM base pairs), in 10 mM phosphate
buffer, pH 7. Inset: Plot of (εa–εf )/(εb–εf ) at (a) 350 nm and (b) 355 nm
vs. equivalents of DNA and the corresponding non-linear fit.
Table 2 DNA binding parameters from fits to absorbance data
Complex
λ(Nap)
ΔAbs
λ(MLCT)
ΔAbs
Binding
constant
K (M−1)
Binding
site size
(base pairs)
Ru·Nap 37% 16% 9.0 × 106(±1.0) M−1 2.18(±0.02)
Ru·2Nap 56% 41% 1.5 × 107(±0.5) M−1 2.48(±0.02)
Table 1 Emission properties of Ru(II) complexes in aerated and
degassed solution at 298 K. All at 6.5 μM concentration. λex 450 nm
Complex
λem
(nm)
Φf (±10%)
aerated
buffer
Φf (±10%)
aerated
acetonitrile
Φf (±10%)
de-gassed
acetonitrile
Ru 670 0.014 0.021 0.061
Ru·Nap 645 0.018 — —
Ru·2Nap 670 0.014 0.021 0.064
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unlikely due to the minimal extended planar nature of the
bipyridine ligands.27 The binding constant K for these inter-
actions was determined as 1.5 × 107 M−1, with a slightly larger
calculated binding site size of 2.48 base pairs. The binding
curve profiles obtained from the UV-visible titrations indicate
that both complexes bind very strongly to DNA. Notably, in the
case of Ru·2Nap changes in the UV-vis absorption spectra are
complicated by the existence of intramolecular π-stacking
interactions between the naphthalimides and/or with the bpy
ligand to which they are coupled. Furthermore, the lack of a
clear isosbestic point in the case of Ru·2Nap possibly reflects
the fact that the flexible linker allows multiple modes of
binding to occur.
DNA binding: emission titrations
Fluorometric DNA titrations were followed by exciting both
chromophores independently at 338 nm and 450 nm. Having
observed that the emission from the Ru(II) centre is sensitised
by energy transfer from the 1,8-naphthalimides, it was
expected that any intercalation of the naphthalimide group
with DNA would result in changes in the photophysical pro-
perties of the complexes. Direct excitation of Ru·Nap metal
centre at 450 nm resulted in a two phase increase in intensity
coinciding with a more gradual increase after the addition of
ca. one base pair equivalent. The emission was found to
plateau at ca. 10 base pair equivalents with an increase in
MLCT emission intensity of 20% observed (Fig. S10 ESI†). It is
possible that the modest increase in intensity observed for
Ru·Nap, is due to protection of the metal centre from quench-
ing by oxygen and solvent molecules upon DNA binding.
MLCT emission observed upon excitation of the Ru·Nap
naphthalimide group at 338 nm, in the presence of DNA, was
found to decrease (ca. −43%) in intensity (Fig. S11 ESI†). A
large decrease in intensity was observed up to the addition of
ca. 3 base pair equivalents, followed by a more gradual
decrease up to ca. 15 base pairs. No concomitant changes were
seen in the 1,8-naphthalimide emission. We can consider that
the binding of the naphthalimide, in the Ru·Nap complex, to
DNA results in (1) positioning of the naphthalimide in a new
chemical environment and (2) the disruption of coupling
between the metal complex centre and naphthalimide. The
effect on the intramolecular coupling is most clearly seen by
comparing the excitation spectra of the complexes recorded in
the presence, and absence of DNA (see Fig. 5). It can be seen
that in the presence of higher concentrations of DNA the exci-
tation spectrum for Ru·Nap closely resembles that of Ru,
which has no appended 1,8-naphthalimides.
Ru·2Nap in the presence of DNA also exhibited complex
emission behaviour. Direct excitation of the MLCT band at
450 nm in the presence of low concentrations of st-DNA
(0–0.45 base pair equivalents) resulted in a modest (25%)
increase in the MLCT emission intensity (Fig. S12 ESI†).
However, in contrast to Ru·Nap, further additions of st-DNA
resulted in a decrease in the emission intensity. The final
intensity represented a decrease of 46% from that of the initial
intensity. In Ru·2Nap excitation of the 1,8-naphthalimide band
at 345 nm yields more pronounced changes in emission inten-
sity, see Fig. 6. An initial increase in intensity (14%) was
observed at base equivalents (up to 0.45 base pairs), followed
by a subsequent decrease of 73% compared to the initial inten-
sity. The behaviour at low Bp/D equivalents is attributed to the
disruption of intramolecular stacking of the 1,8-naphthal-
imides, which occurs in the presence of a small quantity of
DNA. This unstacking is proposed to result in more efficient
energy transfer to the metal.
The overall decrease in intensity may be attributed to
quenching of the 1,8-naphthalimide singlet excited state by
electron transfer from the nucleotides.40 However, in the
absence of electron transfer from a suitable nucleotide the
decrease in intensity may also arise due to disruption of
energy transfer from the naphthalimide to the metal centre
due to the presence of the DNA environment as observed in
the excitation spectrum (Fig. S13 ESI†).
Fig. 5 Excitation spectrum of Ru·Nap (6.5 μM) (λem = 645 nm) in 10 mM
phosphate buffer, at pH 7 in the absence (——) and presence of st-DNA
at a Bp/D ratio of 1 ( ) and 20 ( ).
Fig. 6 (a) Changes in the emission spectrum (λex = 345 nm) of Ru·2Nap
(6.7 μM) in 10 mM phosphate buffer, pH 7 with increasing concentration
of st-DNA (0–60.3 μM).
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Thermal denaturation studies
Thermal denaturation studies were carried out to further eluci-
date the nature of the interaction of Ru·Nap and Ru·2Nap with
DNA. Significant differences in the shifts in the melting temp-
erature (Tm) of DNA were observed in the presence of either
complex. The presence of Ru·Nap resulted in an increase in Tm
from 69 °C to 75.8 °C giving a ΔTm of 6.8 °C, see Fig. 7.
However, a much smaller stabilisation was observed with
Ru·2Nap, giving a shift in Tm of 2 °C. These results suggest
that Ru·Nap binds by a classical intercalative mode but indi-
cate that Ru·2Nap binds in a non-classical mode, such as
partial intercalation and groove binding of the two 1,8-
naphthalimides, which may not stabilise the helix to the same
extent. Given that the stabilisation of the DNA is expected to
be enhanced by electrostatic interactions of the Ru(bpy)3
2+
core with the DNA backbone, the reduced stabilisation
observed for Ru·2Nap compared to Ru·Nap could be due to a
change in the interaction of the metal complex with DNA.
Circular dichroism (CD) and linear dichroism (LD) studies
Circular and linear dichroism53 DNA titrations were also
carried out for both complexes to determine the nature of any
induced chirality in the presence of DNA and to attempt to elu-
cidate their specific mode of DNA interaction. Keeping the
concentration of DNA constant, increased amounts of the com-
plexes were added to give a range of Bp/D ratios. Both conju-
gates were found to display similar CD behaviour. In the case
of Ru·Nap a small induced CD signal was observed at long
wavelength with the maximum appearing at approximately
470 nm for the MLCT absorption band, see Fig. 8a. This obser-
vation confirms that the Ru(II) component of Ru·Nap is associ-
ated with the DNA structure. A small induced CD signal was
observed in the region of absorption of the 1,8-naphthalimide
at 350 nm, however larger signal changes were observed at
lower wavelengths where absorption arises due to both the
naphthalimide and bpy π–π* intraligand transitions. In con-
trast, larger changes in the CD signal were seen in the region
of absorption of DNA, which is possibly due to a combination
of conformational changes of the DNA induced by the bound
complex, or alternatively due to ICD transitions of the bound
complexes themselves. These changes can be clearly seen in
the difference spectra shown in Fig. 8b. The CD spectra
obtained for Ru·2Nap revealed significant changes below
300 nm in the region where DNA absorbs. Interestingly,
weaker signals were observed in the naphthalimide and the
MLCT region, which suggests that the two complexes bind
differently to DNA (see Fig. S14 ESI†).
In an attempt to understand in greater detail the different
binding modes involved, linear dichroism (LD) measurements
were also performed on Ru·Nap and Ru·2Nap in the presence
of DNA. Using this technique intercalative binding gives rise to
absorption minima, while groove binding interactions tends to
result in absorption maxima. The LD spectra of Ru·Nap in the
presence of DNA are shown in Fig. 8c. The DNA bands exhibit
the characteristic absorption minima below 300 nm. In
addition, an absorbance minimum is found in the region of
the 1,8-naphthalimide at 350 nm. This suggests a perpendicu-
lar orientation of the naphthalimide chromophore relative to
the bases (i.e. intercalated between the bases). Significantly,
the MLCT absorption region possesses structured bands with
an absorbance minimum at 420 nm and a maximum at
475 nm. The presence of this structure indicates that the metal
complex is closely associated with the DNA with interactions in
the groove and possible partial intercalation. These results
support our finding above that both components (naphthal-
imide and Ru(II) polypyridyl) are contributing to the overall
binding interaction with DNA, and that the Ru(II) complex is
tightly bound.
In contrast to these results, the LD spectra obtained for
Ru·2Nap in the presence of DNA contained significantly less
structure, see Fig. 8d. This is somewhat surprising giving that
the UV-vis and emission titrations demonstrated that Ru·2Nap
has higher binding affinity for DNA. The LD showed a weakly
absorbing minimum in the region of 1,8-naphthalimide
absorption at 365 nm. This may be explained by the overlap of
the absorbance of the two naphthalimide with different
binding modes. If multiple binding interactions occur with
DNA, for example where only one naphthalimide is bound to
the DNA by intercalation and the other binds via a different
mode e.g. groove binding, the overlap of the negative LD signal
of the intercalating and positive signal of the groove binding
naphthalimides would be expected to reduce the observed LD
signal. The presence of a negative LD signal does, however,
suggest that at least one naphthalimide moiety is binding via
an intercalative mode of binding.
Significantly, no LD signal was observed in the MLCT
region of the spectrum for Ru·2Nap. Indeed, both CD and LD
reveal increased optical activity in the MLCT region of the
spectrum for Ru·Nap compared to the Ru·2Nap. We speculate
that there are two possible origins for this observation. Firstly,
that the binding of the second naphthalimide causes the posi-
Fig. 7 Thermal denaturation curves of st-DNA (150 μM) in 10 mM phos-
phate buffer, at pH 7, in the absence (■) and the presence of Ru·Nap (●)
and Ru·2Nap (▲) at a Bp/D ratio of 5.
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tion and orientation of the metal complex change significantly.
Secondly, as noted for the naphthalimide signal, the presence
of multiple binding orientations may result in overlapping
signals from groove binding and intercalating contacts. This
second observation would be consistent with strong changes
observed for the complex in the MLCT region in the UV-visible
absorption titration (Fig. 4b). In summary, such behaviour
supports the observations from both CD and Tm measure-
ments above, where such differing changes were attributed to
the fact that Ru·Nap is most likely bound by a classical inter-
calative mode, whereas Ru·2Nap likely binds in a more compli-
cated and possibly multimodal manner. The ground and
excited state DNA binding results and the differences seen in
the LD titrations for Ru·Nap and Ru·2Nap clearly demonstrate
that while strong binding can be achieved using two naphthal-
imides, the second naphthalimide moiety can also influence
the binding mode of the Ru(II) centre itself with DNA. Such a
phenomenon has not, to the best of our knowledge, been
demonstrated before using Ru(II)-polypyridyl complexes, flanked
with two identical binding ligands such as the naphthalimide
units in Ru·2Nap. This is a feature that can have the potential to
modulate or tune the ability of such Ru(II)-polypyridyl com-
plexes to interact with DNA, such as their ability to cleave or
damage DNA either in the dark or upon light activation. With
this in mind we set out to probe these potential effects further
using both Ru·Nap and Ru·2Nap.
Photocleavage of DNA by Ru·Nap and Ru·2Nap
The ability of Ru·Nap and Ru·2Nap to cleave pBR322 plasmid
DNA was investigated and compared to that of Ru(bpy)3
2+, see
Fig. 9. The amounts of Form I vs. Form II present are detailed
in Table S1 ESI,† as determined from densitometry measure-
Fig. 9 Agarose gel electrophoresis of pBR322 DNA (1 mg ml−1) after
irradiation at λ > 390 nm in 10 mM phosphate buffer, pH 7. Lane 1:
Plasmid DNA control; Lane 2: Ru(bpy)3
2+ (Bp/D 5) 5 min irradiation;
Lanes 3–5: Ru·Nap (Bp/D 5) 1, 3, 5 min respectively; Lanes 6–8:
Ru·2Nap (Bp/D 5) 1, 3, 5 min respectively.
Fig. 8 Circular dichroism curves of (a) st-DNA (150 μM) in 10 mM phosphate buffer, at pH 7 in the absence and presence of Ru·Nap at varying ratios
and (b) the difference spectra obtained. Linear dichroism curves of st-DNA (150 μM) in 10 mM phosphate buffer, at pH 7.4 in the absence and pres-
ence of (c) Ru·Nap at varying ratios and (d) Ru·2Nap at varying ratios.
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ments of the relative fluorescence intensity of the resulting
bands, that were compared to the control photocleaver
Ru(bpy)3
2+, which was used to evaluate the relative efficiency of
cleavage of the conjugate systems. The presence of Ru(bpy)3
2+
resulted in an increase in Form II after 5 minutes irradiation.§
In the presence of Ru·Nap (Lane 3) a small amount of damage
was also apparent after only 1 min of irradiation, the percen-
tage of Form II having increased to 35%. After 3 minutes
irradiation, this had increased to 49% Form II, and at the
longest irradiation time of 5 minutes had increased to 61%
Form II. From these results, it can be concluded that Ru·Nap
displayed a reasonably efficient photocleavage of DNA, leading
to more pronounced changes than the reference Ru(bpy)3
2+.
In contrast, complex Ru·2Nap resulted in only a minor clea-
vage of the nucleic acid, with Form I being the predominant
DNA species present, even after 5 minutes irradiation. The
different photocleaving ability exhibited by the two complexes
is attributed to their different DNA binding modes which posi-
tion the Ru(II)-polypyridyl centre in different environments.
A reduction in activity is likely to be due to the proximity of
the metal complex to the DNA. This could arise if the complex
was poorly positioned or held away from the DNA bases. On
the other hand, if the complex is very tightly associated with
the DNA groove structure, then access to molecular oxygen
and the photoreactivity would be reduced. This may be the
case for Ru·2Nap. This is a somewhat unexpected result as it
demonstrates that the ‘cooperativity’ that results in increasing
binding affinity can have major and ‘negative’ secondary
effects. Which, as stated above, we believe to be a direct conse-
quence of the positioning of Ru(II)-polypyridyl centre along the
DNA backbone when the second naphthalimide unit is bound.
Cellular uptake, localisation and viability studies
With the aim of using Ru·Nap and Ru·2Nap as dual function-
ing imaging and therapeutic agents, their ability to be interna-
lised in target cells is of vital importance. In order to evaluate
the ability of Ru·Nap and Ru·2Nap to localise within cells,
fluorescence confocal microscopy and cell viability analyses
were undertaken. Confocal microscopy was carried out in
order to provide visual evidence of the localisation of Ru·Nap
and Ru·2Nap in HeLa cervical cancer cells. Populations of live
cells (0.5 × 105) were incubated with both complexes (30 µM) at
37 °C for 4 and 24 h before being treated with the fluorescent
nuclear stain DAPI and viewed using an Olympus FV1000
Fig. 10 Confocal laser scanning microscopy live cell images of Ru·Nap (30 µM) with HeLa cells. Shown are the images obtained with (A) the bright
field view of treated cells after 4 h incubation, stained with DAPI (blue) and Ru·Nap (red), (B) overlay of Ru·Nap (red) and nuclear co-stain DAPI (blue),
(C) Ru·Nap fluorescence alone (red), (D) the bright field view of treated cells after 24 h incubation, stained with DAPI (blue) and Ru·Nap (red), (E)
overlay of Ru·Nap (red) and nuclear co-stain DAPI (blue), (F) Ru·Nap emission alone (red). Compounds were excited by a 488 nm argon laser, emis-
sion 600–700 nm. DAPI was excited by a 405 nm diode laser, emission 410–450 nm.
§Determination of the relative intensity of the bands showed that DNA was
somewhat damaged to begin with, being comprised of 73% Form I and 27%
Form II.
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point scanning microscope with a 60× oil immersion lens.
The results obtained are exemplified in Fig. 10, which shows
the fluorescence confocal laser scanning microscopy images
of live HeLa cells after incubation with Ru·Nap for 4 and 24 h
(the corresponding images for Ru·2Nap are shown in Fig. S15
ESI†). The observed images show the presence of red lumine-
scence emanating from within the cells’ interior, associated
around the nucleus. Although we do not demonstrate co-
localisation with any specific organelles for this study, our pre-
vious work in this area32,54 has demonstrated that related
Ru(II) complexes localise predominantly within the mito-
chondria, leading to perinuclear clustering, with some locali-
sation observed in the lysosomes and the endoplasmic
reticulum. Similar localisation results has been seen by several
other researchers.4a,12a Additionally, cellular viability was
measured using an AlamarBlue assay. Results showed a signifi-
cant reduction in IC50 values following light activation with
compound Ru·Nap, compared to cells maintained in the dark
(7.8 µM versus 30 µM) In contrast, for compound Ru·2Nap,
there was no difference between light and dark IC50 values,
with the cells showing only a small degree of toxicity at the
highest concentration tested, 30 µM, see Table 3. The pro-
duction of reactive oxygen species (ROS) may be a potential
mechanism through which these novel compounds induce
apoptosis.54 Taken together, these results are of considerable
significance in providing evidence for our assertion that the
use of such bifunctional complexes, comprising separate hydro-
philic and hydrophobic centres is a viable means of effecting
cellular accumulation of Ru(II) based probes and reactive agents
within cells for potential diagnostic and therapeutic use.
Conclusions
In conclusion, we have reported the preparation of two new
DNA binding ruthenium complexes appended with one
(Ru·Nap), or two (Ru·2Nap) naphthalimides through flexible
alkyl chain linkers, and investigated their photophysical and
biological properties. The luminescence of the complexes is
found to be solely MLCT based with excitation of the naphthal-
imide centres resulting in MLCT emission, as evidenced from
their excitation spectra. This presents the opportunity to
obtain MLCT-based emission from both complexes through
excitation into either the MLCT or the naphthalimide absorp-
tion bands. These complexes were found to bind strongly to
DNA; demonstrating that our design supports cooperativity,
where the naphthalimide moiety greatly assists in inducing
strong association with DNA by displaying large changes in the
steady state absorption and emission of both complexes. Both
complexes were also shown to exhibit CD activity in the pres-
ence of DNA further confirming their ability to bind strongly
to DNA. The binding mode of these complexes with DNA was
further investigated by observing the changes in the LD
spectra. From the relatively large negative band in the LD spec-
trum when bound to DNA, Ru·Nap appeared to bind to DNA
via intercalation of the naphthalimide moiety; this being
further supported by a large ΔTm. In contrast, Ru·2Nap was
shown to bind to DNA in a more complex fashion; this being
evident from the small LD signal of the naphthalimide moiety
when bound to DNA and a small ΔTm. This is an extremely
important result as it clearly demonstrates that a strong associ-
ation with the DNA is maintained between the naphthalimide
and the Ru(II)-polypyridyl unit in the case of Ru·Nap. However,
in the case of Ru·2Nap, the picture is more complicated, as
here, both the naphthalimide units are bound to DNA causing
a change in the position of the Ru(II)-polypyridyl centre at the
DNA backbone. The result of this change in binding manifests
in the difference in photoreactivity between the two complexes
in the presence of DNA. Upon light activation Ru·Nap was
shown to effectively cleave plasmid DNA while Ru·2Nap
showed poor cleavage. Moreover, this difference in photo-
reactivity in vitro was also observed in cellulo. While both com-
plexes are readily taken up by HeLa cells and emission from
both complexes was observed within the cells after 4 hours
incubation (the complexes were observed to cluster next to the
nucleus), Ru·Nap was found to reduce HeLa cell viability upon
photoactivation, whereas Ru·2Nap was nontoxic under identi-
cal conditions. The results presented herein demonstrate
different activity observed for two closely related conjugates
Ru·Nap and Ru·2Nap, where the structural difference is the
presence of a second naphthalimide unit in Ru·2Nap, does
lead to cooperativity in DNA binding. Such modification
however, can have a detrimental effect on their biological
activity when such structures are considered as potential thera-
peutic agents. To the best of our knowledge this has not pre-
viously been observed or postulated for such systems when
designing DNA targeting and responsive therapeutics. Such
properties are highly desirable when one considers the appli-
cations of such structures as imaging agents for use in mole-
cular biology, as Ru·2Nap is not particularly toxic upon light
irradiation. Hence, while Ru·Nap is a potential candidate for
use in therapy, Ru·2Nap, is a potential candidate for use in
florescence imaging. We are currently investigating this and
such functions of other Ru(II) based polypyridyl complexes in
greater detail.
Experimental
Materials and instrumentation
All reagents and solvents were purchased commercially and
used without further purification unless otherwise stated.
Table 3 The effects of Ru·Nap and Ru·2Nap on HeLa cells with or
without light activation as determined using an AlamarBlue viability
assay
IC50 value (µM) Dark Light activation
Ru·Nap 29.8 7.81
Ru·2Nap >30 >30
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Anhydrous solvents were prepared using standard procedures,
according to Vögel, with distillation under argon prior to each
use. Solutions of DNA in 10 mM phosphate buffer (pH 7) gave
a ratio of UV absorbance at 260 and 280 nm of 1.86 : 1, indicat-
ing that the DNA was sufficiently free of protein. Its concen-
tration was determined spectrophotometrically using the
molar absortivity of 6600 M−1 cm−1 (260 nm).
All NMR spectra were recorded using a Brüker DPX-400
Avance spectrometer, operating at 400.13 MHz for 1H NMR
and 100.6 MHz for 13C NMR, or a Brüker AV-600 spectrometer,
operating at 600.1 MHz for 1H NMR and 150.2 MHz for
13C NMR. Shifts are referenced relative to the internal solvent
signals. Electrospray mass spectra were recorded on a Micro-
mass LCT spectrometer, running Mass Lynx NT V 3.4 on
a Waters 600 controller connected to a 996 photodiode
array detector with HPLC-grade methanol or acetonitrile. High
resolution mass spectra were determined by a peak matching
method, using leucine Enkephalin, (Tyr-Gly-Gly-Phe-Leu), as
the standard reference (m/z = 556.2771). Melting points were
determined using an IA9000 digital melting point apparatus.
Infrared spectra were recorded on a Perkin Elmer Spectrum
One FT-IR spectrometer fitted with a Universal ATR Sampling
Accessory. Elemental analysis was conducted at the Micro-
analytical Laboratory, School of Chemistry and Chemical
Biology, University College Dublin.
UV-visible absorption spectra were recorded on a Varian
Cary 50 spectrometer. Emission spectra were recorded on a
Cary Eclipse Luminescence spectrometer. The luminescence
quantum yields were calculated by comparison with [Ru-
(bpy)3]
2+. Circular dichroism (CD) spectra were recorded at a
concentration corresponding to an optical density of approxi-
mately 1.0, in buffered solutions, on a Jasco J-810-150S
spectropolarimeter.
Biological investigations
Cell culture. HeLa cells were grown in Dulbecco’s Modified
Eagle Medium supplemented with 10% fetal bovine serum
and 50 µg per ml penicillin/streptomycin at 37 °C in a humidi-
fied atmosphere of 5% CO2.
Viability assay. 5 × 103 cells per well were seeded in a
96-well plate and treated with the respective compound for
24 h + irradiation with 18 J cm−2 of light using a Hamamatsu
L2570 200 Watt HgXe Arc Lamp equipped with a NaNO2 filter
for 60 min. After 24 h, each well was then treated with 20 µl
of Alamar Blue (BioSource) (pre-warmed to 37 °C) and left to
incubate at 37 °C in the dark for 4–6 h. Fluorescence was read
using at 590 nm (excitation 544 nm). The control untreated
cells represented 100% cell viability. All data points (expressed
as means ± S.E.M.) were analysed using GRAPHPAD Prism
(version 4) software (Graphpad software Inc., San Diego, CA).
Confocal microscopy. HeLa cells were seeded at a density of
1 × 105 cells per 2 ml, left for 24 h before the required treat-
ment. Cells were then washed twice, stained with and analysed
by live confocal microscopy using an Olympus FV1000 point
scanning microscope with a 60× oil immersion lens with an
NA (numerical aperture) of 1.42. The software used to collect
images was FluoView Version 7.1 software. Compounds
were excited by a 488 nm argon laser, emission 600–700 nm.
DAPI was excited by a 405 nm diode laser, emission
410–450 nm.
N-[(tert-Butoxycarbonyl)-5-aminopentyl]-1,8-naphthalmide (1).
1,8-Naphthalic anhydride (0.80 g, 4.04 mmol, 1 eq.), N-(tert-
butoxycarbonyl)-1,5-diaminopentane (0.90 g, 4.45 mmol,
1.1 eq.), and Et3N (1.23 g, 1.69 ml, 12.12 mmol, 3 eq.) were
added to anhydrous toluene (60 ml) and the mixture heated at
reflux for 24 h. The mixture was filtered hot through celite and
concentrated under vacuum. The residue was dissolved in
CH2Cl2 (100 ml), washed with 0.1 M HCl (2 × 20 ml), water
(20 ml), dried over MgSO4 and concentrated under vacuum.
The product was obtained as an orange oily solid without need
for further purification (0.57 g, 82%). 1H NMR (DMSO[D6],
400 MHz, δ) 8.53 (2H, d, J = 7.6 Hz), 8.49 (2H, d, J = 8.5 Hz),
7.91 (2H, m), 6.82 (1H, s), 4.07 (2H, t, J = 7.0 Hz), 2.94 (2H, d,
J = 6.0 Hz), 1.65 (2H, m), 1.40 (13H, m); 13C NMR (DMSO[D6],
100 MHz, δ) 163.4, 155.6, 134.3, 131.3, 130.7, 127.4, 122.1,
77.3, 54.9, 50.8, 29.2, 28.2, 27.3, 23.8; ESI-MS m/z 405.1809
(M + Na)+; IR (ATR, cm−1): 1698 (m, –CO–N–CO–), 1656
(s, –CONH–)
N-(Pentylammonium)-1,8-naphthalimide trifluoroacetate (2).
Compound 1 (0.88 g, 2.29 mmol, 1 eq.) was stirred in TFA
(15 ml) for 1 h at room temperature. The TFA was removed
under vacuum and co-evaporated several times with CH2Cl2.
After drying under high vacuum the solid was obtained as a
pale brown solid (0.90 g, 99%). 1H NMR (CD3OD, 400 MHz, δ)
8.30 (2H, d, J = 7.6 Hz), 8.11 (2H, d, J = 8.0 Hz), 7.62 (2H, t, J =
7.5 Hz), 4.04 (2H, m), 2.97 (2H, m), 1.74 (4H, m,), 1.48 (2H, m);
13C NMR (CD3OD, 100 MHz, δ) 163.8, 133.8, 113.2130.3, 127.2,
126.3, 121.5, 39.0, 38.8, 26.6, 26.3, 23.0; ESI-MS m/z 283.1456
(M)+; IR (ATR, cm−1): 3179 (w, –NH2), 1694 (m, –CO–N–CO–);
m.p 151–152 °C.
4-[N-(Pentylcarboxamide)-1,8-naphthalimide]-4′-methyl-2,2′-
bipyridine (3a). Compound 2 (0.15 g, 0.38 mmol, 1.1 eq.) and
Et3N (0.10 g, 0.14 ml, 1.02 mmol, 3 eq.) were dissolved in
dry CH2Cl2 and 4-(carbonylchloride)-4′-methyl-2,2′-bipyridine
(0.08 g, 0.34 mmol, 1 eq.) dissolved in dry CH2Cl2, was added
dropwise. The solvent was removed under reduced pressure.
The resulting residue was stirred with 0.1 M HCl, filtered
and washed with water. Purification was performed by silica
column chromatography eluting with CH2Cl2/MeOH 10% the
product was obtained as a pale brown solid (0.14 g, 83%); cal-
culated for C29H26N4O3·0.25CH2Cl2: C, 70.29; H, 5.34; N, 11.21.
Found: C, 70.62; H, 5.48; N, 10.84; 1H NMR (DMSO[D6],
400 MHz, δ): 8.90 (1H, m, NH ̲), 8.76 (1H, d, J = 5.0 Hz, Bpy-H̲),
8.71 (1H, s, Bpy-H̲), 8.57 (1H, d, J = 5.0 Hz, Bpy-H̲), 8.48 (2H, d,
J = 7.0 Hz, Naph-H̲), 8.44 (2H, d, J = 8.0 Hz, Naph-H ̲), 8.26 (1H,
s, Bpy-H̲), 7.85 (2H, m, Naph-H̲), 7.73 (1H, dd, J = 1.5, 5.0 Hz,
Bpy-H̲), 7.33 (1H, d, J = 4.5 Hz, Bpy-H̲), 4.07 (2H, t, J = 7.6 Hz,
CH̲2), 3.29 (2H, m, CH̲2), 2.44 (3H, s, CH̲3), 1.71 (2H, m, CH̲2),
1.63 (2H, m, CH̲2), 1.41 (2H, m, CH̲2); IR (ATR, cm
−1): 1698 (m,
–CO–N–CO–), 1658 (s, –CONH–); m.p. 162–164 °C.
4,4′-Bis-[(N-pentylcarboxamide)-1,8-naphthalimide]-2,2′-
bipyridine (3b). Was prepared as above with compound 2
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(0.40 g, 1.01 mmol, 2.1 eq.) and 4,4′-bis(carbonylchloride)-2,2′-
bipyridine (0.14 g, 0.48 mmol, 1 eq.). The product was
obtained as a purple solid (0.35 g, 95%). 1H NMR (DMSO[D6],
400 MHz, δ) 8.97 (1H, br s, NH ̲), 8.80 (1H, m, Bpy-H̲), 8.75 (1H,
m, Bpy-H̲), 8.46 (2H, d, J = 7.0 Hz, Naph-H̲), 8.42 (2H, d, J =
8.0 Hz, Naph-H̲), 7.83 (2H, m, Naph-H̲), 7.77 (1H, m, Bpy-H̲),
4.06 (2H, m, CH̲2), ∼3.30 (CH̲2, under solvent peak – from CH
COSY), 1.69 (2H, m, CH̲2), 1.63 (2H, m, CH̲2), 1.41 (2H, m,
CH̲2);
13C NMR (DMSO[D6], 150 MHz, δ) 164.8, 163.7, 155.8,
150.2, 143.3, 134.5, 131.6, 131.0, 127.7, 127.5, 122.4, 122.2,
118.5, 40.1, 39.7, 28.9, 27.6, 24.3; IR (ATR, cm−1): 1698
(w, –CO–N–CO–), 1658 (m, –CONH–); m.p 210–211 °C.
RuNap. Compound 3a (0.09 g, 0.19 mmol, 1 eq.) and
Ru(bpy)2Cl2·2H2O (0.12 g, 0.23 mmol, 1.2 eq.) were suspended
in DMF/H2O (20 ml) and the solution degassed by bubbling
with Argon for 10 min. The reaction mixture was heated at
reflux under an Argon atmosphere for 20 h. The solvent was
removed under vacuum. The residue was dissolved in water
and filtered. To the filtrate was added a concentrated aqueous
solution of NH4PF6, and the resulting precipitate extracted
into CH2Cl2. The product was purified by silica flash column
chromatography eluting with CH3CN/H2O/NaNO3(sat) 40 : 4 : 1.
The chloride salt of the complex was reformed by stirring a
solution of the complex in MeOH with Amberlite ion exchange
resin (Cl− form). The chloride salt was further purified by
column chromatography on Sephadex LH-20 eluting with
methanol giving them product as a red/brown solid (0.16 g,
86%). Calculated for C49H42F12N8O3P2Ru·CH3CN: C, 50.09; H,
3.71; N, 10.31. Found: C, 50.38; H, 3.43; N, 10.39% accurate
MS (m/z) calculated for C49H42N8O3Ru (M
2+): 892.2423. Found
892.2420; 1H NMR (CD3CN, 400 MHz, δ): 8.90 (1H, d, J =
1.5 Hz), 8.60 (1H, s), 8.51 (6H, m), 8.34 (2H, d, J = 7.5 Hz), 8.08
(4H, m), 7.82 (2H, m), 7.76 (6H, m), 7.63 (1H, dd, J = 1.5,
6.0 Hz), 7.57 (2H, d, J = 6.0 Hz), 7.40 (4H, m), 7.29 (1H, d, J =
5.5 Hz), 4.13 (2H, t, J = 7.5 Hz), 3.43 (2H, m), 2.56 (3H, s), 1.74
(4H, m), 1.49 (2H, m); 13C NMR (CD3CN, 150 MHz, δ): 163.9,
162.9, 157.8, 156.9, 156.84, 156.80, 156.7, 156.0, 152.1, 151.6,
151.5, 151.4, 150.6, 142.7, 137.7, 133.9, 131.6, 130.5, 128.5,
127.9, 127.5, 126.9, 125.5, 124.4, 124.2, 124.1, 122.7, 121.5,
39.7, 39.6, 28.5, 27.3, 24.0, 20.1; IR (ATR, cm−1): 1698 (m, –CO–
N–CO–), 1658 (m, –CONH–).
Ru·2Nap. Was prepared as above, using (0.115 g,
0.15 mmol, 1 eq.) of compound 3b and (0.085 g, 0.16 mmol,
1.1 eq.) Ru(bpy)2Cl2·2H2O. Product as a red/brown solid
(0.142 g, 76%). Found C, 51.94; H, 3.81; N, 8.92%
C66H56F12N10O6P2Ru·3H2O requires C, 51.80; H, 4.08; N,
9.15%; 1H NMR (CD3OD, 400 MHz, δ) 9.34 (1H, s), 8.76 (2H,
dd, J = 3.0, 8.0 Hz), 8.33 (2H, d, J = 7.0 Hz), 8.18 (4H, m), 8.02
(1H, d, J = 5.5 Hz), 7.86 (3H, m), 7.64 (2H, m), 7.54 (2H, pent,
J = 6.5 Hz), 4.06 (2H, t, J = 7.6 Hz), 3.45 (2H, m), 1.73 (4H, m),
1.49 (2H, m); 13C NMR (CD3OD, 100 MHz, δ) 164.44, 164.39,
158.0, 157.4, 157.3, 152.4, 151.8, 151.6, 143.2, 138.6, 134.4,
131.9, 130.9, 128.13, 128.1, 128.0, 127.0, 125.8, 124.8,
122.5, 122.4, 40.2, 40.1, 28.9, 27.7, 24.5; ESI-MS m/z 1186.3412
(M)+; IR (ATR, cm−1): 1695 (m, –CO–N–CO–), 1652 (s,
–CONH–).
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